Clinical Trials Logo
  1. Home
  2. Post-Traumatic Stress Disorder
  3. NCT04951076

A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD) — ATTUNE  

Post-Traumatic Stress Disorder Clinical Trial

Official title:
A Phase 2b, Randomized, Double Blind, Two Arm Study to Investigate the Effects of BNC210 Tablet Formulation Compared to Placebo in Adults With Post-Traumatic Stress Disorder (PTSD)

Clinical Trial Summary

The purpose of this study is to assess the effects of BNC210 compared to placebo on PTSD symptom severity as measured by CAPS-5 Total Symptom Severity Scores.

Clinical Trial Description

This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study with a 12 week, 2-arm treatment period. Participants will attend a Screening visit within 3 weeks before randomization to confirm eligibility. Approximately 200 participants will be randomized using a 1:1 ratio to receive either BNC210 900 mg twice daily (b.i.d.) or matched placebo. Participants will then complete 12 weeks of treatment with their allocated study intervention. Participants will return to their study site at 4-weekly intervals to receive study intervention and complete safety and efficacy assessments. Participants are then requested to attend a Follow-up visit at Week 15 (i.e., 3 weeks after their last study intervention is administered). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04951076
Study type Interventional
Source Bionomics Limited
Contact
Status Completed
Phase Phase 2
Start date July 27, 2021
Completion date August 14, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04317820 - Deep Brain Reorienting in Post-traumatic Stress Disorder N/A
Completed NCT05112003 - Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot N/A
Recruiting NCT04518267 - Anger and Psychotrauma: Data From Military and Civilians
Completed NCT02502604 - Cognitive Training Program for Individuals With Depression and Post-Traumatic Stress Disorder N/A
Completed NCT02256566 - Cognitive Training for Mood and Anxiety Disorders N/A
Terminated NCT02234687 - A mGlu2/3 Agonist in the Treatment of PTSD Phase 1
Completed NCT02213900 - Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy Phase 4
Terminated NCT02520726 - PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims Phase 4
Completed NCT01738308 - The Effects of Healing Touch on Post Operative Pediatric Patients N/A
Completed NCT01437891 - Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder (PTSD) and Gulf War Fibromyalgia (GWF) N/A
Completed NCT01517711 - Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Phase 4
Completed NCT01998100 - Maximizing Treatment Outcome in Post-Traumatic Stress Disorder (PTSD) Phase 3
Completed NCT01199107 - Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD) Phase 3
Completed NCT01231711 - Improving Quality-of-life and Depressive Symptoms of Combat Veterans Via Internet-based Intervention Phase 1
Completed NCT00348036 - Group Intervention for Interpersonal Trauma N/A
Completed NCT00838006 - Psychophysiologic Predictors of Post-deployment Mental Health Outcomes N/A
Completed NCT00680524 - Telephone-based Care for OEF/OIF Veterans With PTSD N/A
Completed NCT00525226 - Evaluating the Effects of Stress in Pregnancy N/A
Completed NCT00158262 - Effect of Propranolol on Preventing Posttraumatic Stress Disorder Phase 4
Completed NCT00127673 - Comparison of Two Treatments for Post-Traumatic Stress Disorder Phase 3